About

Daniel M. Schmitt has served as Actuate Therapeutics' President and Chief Executive Officer since March 2015 and as a director since April 2015. He brings more than 30 years of pharmaceutical and biotechnology experience across operations management, new product development and business development, and has led high-value licensing, acquisition and development transactions. He previously served as Chief Operating Officer of Genus Oncology, LLC from 2009 to 2014; Senior Vice President, Licensing and Commercial Development of Immtech Pharmaceuticals, Inc. from 2004 to 2009; and General Manager, Academic and Government Institution Markets of First Genetic Trust from 2001 to 2004, and earlier held positions with G.D. Searle, ILEX Oncology, Fujisawa USA and Burroughs Wellcome. He is a founding member of Chicago Innovation Mentors and earned an M.B.A. and a B.S. in Chemistry from West Virginia University.

Roles

Actuate Therapeutics, Inc.
President, Chief Executive Officer & Director · Current role
March 2015–present
Actuate Therapeutics, Inc.
President & Chief Executive Officer
2015 - present
Genus Oncology, LLC
Chief Operating Officer
2009 - 2014
Immtech Pharmaceuticals, Inc.
SVP, Licensing & Commercial Development
2004 - 2009
First Genetic Trust
General Manager, Academic & Government Institution Markets
2001 - 2004

Fixed Compensation

FY 2025
Salary
$570,000
ComponentAnnual base salary earned in 2025
Total compensation
$2,166,522

Performance Compensation

Data from FY 2025

Cash incentive

Bonus
$142,329
Target Opportunity
PlanDiscretionary annual cash bonus

Stock awards

Option awards
$1,454,193
FormStock options, ASC 718 grant-date fair value

Also at Actuate Therapeutics, Inc.

Related

See how VectorShift works for your firm

Request Demo